Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S; GLOBAL LEADERS Investigators.
Lancet. 2018 Sep 15;392(10151):940-949. doi: 10.1016/S0140-6736(18)31858-0. Epub 2018 Aug 27.
Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial.
Ali ZA, Maehara A, Généreux P, Shlofmitz RA, Fabbiocchi F, Nazif TM, Guagliumi G, Meraj PM, Alfonso F, Samady H, Akasaka T, Carlson EB, Leesar MA, Matsumura M, Ozan MO, Mintz GS, Ben-Yehuda O, Stone GW; ILUMIEN III: OPTIMIZE PCI Investigators.
Lancet. 2016 Nov 26;388(10060):2618-2628. doi: 10.1016/S0140-6736(16)31922-5. Epub 2016 Oct 30.
Coronary artery bypass grafting versus drug-eluting stent implantation for left main coronary artery disease (from a two-center registry).
Kang SH, Park KH, Choi DJ, Park KW, Chung WY, Lim C, Kim KB, Kim HS.
Am J Cardiol. 2010 Feb 1;105(3):343-51. doi: 10.1016/j.amjcard.2009.09.036.
Predictors of Irregular Protrusion After Everolimus-Eluting Stent Implantation in Patients with Stable Coronary Artery Disease.
Taguchi Y, Itoh T, Sasaki W, Oda H, Uchimura Y, Kaneko K, Sakamoto T, Goto I, Sakuma M, Ishida M, Terashita D, Otake H, Morino Y, Shinke T.
Int Heart J. 2022;63(2):210-216. doi: 10.1536/ihj.21-548.
Comparison of noninvasive follow-up testing in patients after percutaneous coronary intervention with drug-eluting stent implantation.
Seki T, Takeuchi M, Kawakami K.
J Cardiol. 2022 Sep;80(3):275-282. doi: 10.1016/j.jjcc.2022.05.001. Epub 2022 May 21.
Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial.
van Geuns RJ, Chun-Chin C, McEntegart MB, Merkulov E, Kretov E, Lesiak M, O'Kane P, Hanratty CG, Bressollette E, Silvestri M, Wlodarczak A, Barragan P, Anderson R, Protopopov A, Peace A, Menown I, Rocchiccioli P, Onuma Y, Oldroyd KG.
EuroIntervention. 2022 Apr 22;17(18):1467-1476. doi: 10.4244/EIJ-D-21-00514.
Five-year comparative study of thin-strut rapamycin-eluting bioabsorbable scaffold with metallic drug-eluting stent in porcine coronary artery.
Liu Y, Zheng B, Zhang B, Ndondo-Lay R, Nie F, Tang N, Miao Y, Li J, Huo Y.
Front Cardiovasc Med. 2022 Jul 22;9:938519. doi: 10.3389/fcvm.2022.938519. eCollection 2022.
Comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease: a meta-analysis.
Li X, Kong M, Jiang D, Dong A.
Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):347-54. doi: 10.1093/icvts/ivt509. Epub 2013 Dec 16.
Drug-eluting stent for unprotected left main coronary artery disease: early and mid-term outcomes.
Tassanawiwat W, Mahavanakul W, Thanakitcharu P, Komolsart P, Chansod S, Sookananchai B, Wongvipaporn C, Kiatchoosakun S, Cheiniwat S, Tresukosol D.
J Med Assoc Thai. 2010 Sep;93(9):1030-6.
Percutaneous Treatment of Unprotected Left Main Disease With Thin-Strut Durable-Polymer or Early Generation Thicker-Strutted and Coated Bioabsorbable-Polymer Drug-Eluting Stents in a Large-Scale Registry.
Lee MS, Kang J, Park KW, Cho H, Lee HS, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS.
Cardiovasc Revasc Med. 2021 Nov;32:43-49. doi: 10.1016/j.carrev.2020.12.034. Epub 2020 Dec 31.
